GAS41 Revisited: A Chemical Probe

Why It Matters

A potent, cell‑active GAS41 probe provides a reliable tool to dissect epigenetic regulation in NSCLC, accelerating target validation and drug discovery.

Key Takeaways

• DLG-41 binds GAS41 with ~1 µM ITC affinity.
• Nanomolar cellular activity confirmed via NanoBRET assay.
• Negative control DLG-41nc shows >25 µM IC50, negligible activity.
• DLG-41 inhibits proliferation in NSCLC cell lines.
• Probe meets near‑threshold criteria for chemical probe standards.

Pulse Analysis

The YEATS domain of GAS41 functions as an epigenetic reader, recognizing acetyl‑lysine marks on chromatin and influencing transcriptional programs linked to tumor growth. Early fragment screens identified a weak binder, but subsequent structure‑guided iterations have transformed that scaffold into a high‑quality chemical probe. By focusing on monomeric designs rather than bulky dimers, the team achieved a balance between affinity and drug‑like properties, positioning DLG‑41 as a versatile tool for mechanistic studies in oncology.

DLG‑41’s biochemical profile is anchored by a 1 µM dissociation constant measured via isothermal titration calorimetry, while its nanomolar IC₅₀ in NanoBRET assays demonstrates robust cellular permeability and on‑target engagement. The inclusion of DLG‑41nc, a thiazole‑substituted analogue lacking activity, satisfies best‑practice guidelines for probe validation, offering a clear negative control for phenotypic experiments. In vitro, DLG‑41 curtails proliferation in a panel of NSCLC cell lines, and transcriptomic analyses reveal widespread gene‑expression shifts consistent with GAS41 inhibition.

Beyond its immediate experimental utility, DLG‑41 exemplifies how academic fragment‑based programs can deliver probes that meet the 2015 chemical‑probe standards, bridging the gap between basic epigenetic research and translational drug discovery. Its demonstrated efficacy in lung‑cancer models may inspire medicinal chemists to pursue optimized derivatives with therapeutic intent, while the probe itself will likely become a staple in studies probing YEATS‑domain biology across cancer types.